Drug intelligence / Profile preview

docetaxel + mitoxantrone

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Intravenous

Overview

A chemotherapy regimen consisting of docetaxel and mitoxantrone, primarily studied in sequential rather than simultaneous administration for hormone-refractory prostate cancer (HRPC). Docetaxel is a taxoid that has demonstrated superior survival outcomes compared to mitoxantrone when used as first-line therapy. When used sequentially, patients receiving docetaxel first-line followed by mitoxantrone showed better survival outcomes than the reverse sequence.

Brand names: NovantroneTaxotere
Other names: mitoxantrone-OHSU Knight Cancer Institute-prostate cancermitoxantrone hydrochloridedocetaxel

Targets

TOP2B (DNA topoisomerase II beta)TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on docetaxel + mitoxantrone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + mitoxantrone.

Explore the full profile